A proof-of-concept study to evaluate 99mTechnetium radiolabelled Fucoidan as diagnostic modality for thrombosis

A proof-of-concept study to evaluate 99mTechnetium radiolabelled Fucoidan as diagnostic modality for thrombosis - Fucoidan-DVT

Status

Recruiting

Phases

Phase 2

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47990

Enrollment

Registered

2019-04-26

Start date

2019-11-27

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with a blood clot in one of the legs patients with deep venous thrombosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Adult subjects of either gender, aged 50 years or older, with a compression ultra-sound demonstrated acute DVT,

Exclusion criteria

Exclusion criteria: - Standard contra-indications to SPECT - Any medical condition or treatment that could interfere with the conduct of the study in the opinion of the investigator - Inability or unwilling to comply with protocol requirements, or deemed by the investigator to have a disorder that may compromise the ability to give informed consent

Design outcomes

Primary

Measure	Time frame
To assess the difference in uptake of 99mTc-Fucoidan in the affected vein versus the corresponding vein in the unaffected leg of patients with acute DVT.	—

Secondary

Measure	Time frame
To assess the effect of of Fucoidan on monocyte-endothelial and monocyte-platelet interaction in stimulated endothelium ex vivo	—

Countries

Netherlands

Outcome results